CDP and RDP as Alternatives to TPhP: Comparative Effects on Glucose Homeostasis and Hepatic and Whole-Pancreas Molecular Endpoints in Mice.
4 affiliations
- 1Key Laboratory of Yangtze River Water Environment, College of Environmental Science and Engineering, Tongji University, 1239 Siping Road, Shanghai 200092, China.
- 2Shanghai Institute of Pollution Control and Ecological Security, College of Environmental Science and Engineering, Tongji University, 1239 Siping Road, Shanghai 200092, China.
- 3Department of Pathology and Pathophysiology, Teaching Laboratory Center, School of Medicine, Tongji University, Shanghai 200331, China.
- 4Department of Criminal Science and Technology, Shandong Police College, Jinan 250200, China.
Abstract
Organophosphate flame retardants (OPFRs) are widely used as replacements for brominated flame retardants, yet the metabolic effects of cresyl diphenyl phosphate (CDP) and resorcinol bis(diphenyl phosphate) (RDP), two structurally related alternatives to the major aryl OPFR triphenyl phosphate (TPhP), remain poorly characterized. Male C57BL/6J mice received TPhP, CDP, or RDP by oral gavage every 3 days for 70 days at time-weighted average doses of 20 ng/kg body weight/day or 20 μg/kg body weight/day. The lower level was exposure-informed; the higher level served as a toxicological contrast. Glucose tolerance, systemic insulin responsiveness, and hepatic and whole-pancreas biochemical, histological, transcriptomic, and protein endpoints were evaluated. All three compounds altered glucose homeostasis, with overlapping but compound-dependent effects. Hepatic measurements showed lower insulin-signaling and glycogen-storage markers, including lower post-insulin AKT phosphorylation. Whole-pancreas measurements showed lower ESRRG and higher LDHA abundance, generating hypotheses about metabolic and secretion-associated pathways. Across the measured endpoints, CDP and RDP did not show a consistently smaller metabolic response than TPhP. Thus, their substitution cannot be presumed to improve metabolic safety. This comparison is restricted to the tested nominal doses and intermittent oral-gavage regimen; it does not establish overall toxicity or internal-dose-normalized relative potency. Internal dosimetry and comparisons with continuous exposure are needed to assess the relevance to human exposure.
Related
- Prometheus’s Fire, Part II: The Hydra of Inflammation—Multiorgan Self-Amplifying Inflammatory Loops in Obesity: Molecular Crosstalk Between Adipose Tissue, Liver, Skeletal Muscle, Pancreas and Cardiovascular System
- Comparative Effects of Acrolein and Glyoxal on Redox Homeostasis, Antioxidant Defense and Membrane Properties in Human Peripheral Blood Mononuclear Cells: An In Vitro Study.
- Comparative analysis of the hemodynamic and metabolic effects of alternative fluid resuscitation strategies in critically ill patients with combined chest trauma and hemorrhagic shock: impact on oxygen delivery-consumption balance and coagulation homeostasis.
- Autophagy in Pituitary Neuroendocrine Tumors (PitNETs): Molecular Mechanisms, Secretory Homeostasis, Therapeutic Resistance, and Translational Perspectives
- α-Lipoic Acid and Deferoxamine Restore Redox–Metallomic Homeostasis in Dapsone Toxicity: Integrated Biochemical, Histological, and Molecular Modeling Evidence
BibTeX
@article{chang2026alternatives,
title = {{CDP and RDP as Alternatives to TPhP: Comparative Effects on Glucose Homeostasis and Hepatic and Whole-Pancreas Molecular Endpoints in Mice.}},
author = {Jiajun Chang and Zhuozhuo Wang and Yao Xiao and Yifan Liu and Yuan Meng and Qinghui Huang and Zhiliang Zhu and Daqiang Yin and Xiaojuan Xu and Yanling Qiu},
journal = {Toxics},
year = {2026},
month = sep,
doi = {10.3390/toxics14100841},
url = {https://europepmc.org/article/MED/42931628},
note = {CC BY},
}
RIS
TY - JOUR
TI - CDP and RDP as Alternatives to TPhP: Comparative Effects on Glucose Homeostasis and Hepatic and Whole-Pancreas Molecular Endpoints in Mice.
AU - Jiajun Chang
AU - Zhuozhuo Wang
AU - Yao Xiao
AU - Yifan Liu
AU - Yuan Meng
AU - Qinghui Huang
AU - Zhiliang Zhu
AU - Daqiang Yin
AU - Xiaojuan Xu
AU - Yanling Qiu
PY - 2026
DA - 2026/09/22
JO - Toxics
DO - 10.3390/toxics14100841
UR - https://europepmc.org/article/MED/42931628
AB - Organophosphate flame retardants (OPFRs) are widely used as replacements for brominated flame retardants, yet the metabolic effects of cresyl diphenyl phosphate (CDP) and resorcinol bis(diphenyl phosphate) (RDP), two structurally related alternatives to the major aryl OPFR triphenyl phosphate (TPhP), remain poorly characterized. Male C57BL/6J mice received TPhP, CDP, or RDP by oral gavage every 3 days for 70 days at time-weighted average doses of 20 ng/kg body weight/day or 20 μg/kg body weight/day. The lower level was exposure-informed; the higher level served as a toxicological contrast. Glucose tolerance, systemic insulin responsiveness, and hepatic and whole-pancreas biochemical, histological, transcriptomic, and protein endpoints were evaluated. All three compounds altered glucose homeostasis, with overlapping but compound-dependent effects. Hepatic measurements showed lower insulin-signaling and glycogen-storage markers, including lower post-insulin AKT phosphorylation. Whole-pancreas measurements showed lower ESRRG and higher LDHA abundance, generating hypotheses about metabolic and secretion-associated pathways. Across the measured endpoints, CDP and RDP did not show a consistently smaller metabolic response than TPhP. Thus, their substitution cannot be presumed to improve metabolic safety. This comparison is restricted to the tested nominal doses and intermittent oral-gavage regimen; it does not establish overall toxicity or internal-dose-normalized relative potency. Internal dosimetry and comparisons with continuous exposure are needed to assess the relevance to human exposure.
SN - 2305-6304
ER -